Erika Valeri

Erika Valeri

Auto-generated profile, based on publicly available information

Erika Valeri

Research Institute of Molecular Pathology (IMP), Vienna Biocenter (VBC), Vienna, Austria

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 July 2024 in Journal of Experimental Medicine
Verified
Journal Article
Open access
EVErika Valeri
Erika Valeri
SBSara Breggion
Sara Breggion
FBFederica Barzaghi
Federica Barzaghi
MAMonah Abou Alezz
Monah Abou Alezz
GCGiovanni Crivicich
Giovanni Crivicich
AKAnna Kajaste-Rudnitski
Anna Kajaste-Rudnitski
Gain-of-function mutations in STING cause STING-associated vasculopathy with onset in infancy (SAVI) characterized by early-onset systemic inflammation, skin vasculopathy, and interstitial lung disease. Here, we report and characterize a novel STING variant (F269S) identified in a SAVI patient. Single-cell transcriptomics of patient bone marrow revealed spontaneous activation of interferon (IFN) and inflammatory pathways across cell types and a striking prevalence of circulating naïve T cells was observed. Inducible STING F269S expression conferred enhanced signaling through ligand-independent translocation of the protein to the Golgi, protecting cells from viral infections but preventing their efficient immune priming. Additionally, endothelial cell activation was promoted and further exacerbated by cytokine secretion by SAVI immune cells, resulting in inflammation and endothelial damage. Our findings identify STING F269S mutation as a novel pathogenic variant causing SAVI, highlight the importance of the crosstalk between endothelial and immune cells in the context of lung disease, and contribute to a better understanding of how aberrant STING activation can cause pathology.

6 December 2024 in Journal of Experimental Medicine
Verified
Journal Article
Open access
EVErika Valeri
Erika Valeri
AKAnna Kajaste-Rudnitski
Anna Kajaste-Rudnitski
Two complementary works by Chan et al. (https://doi.org/10.1084/jem.20231725), and Ru et al. (https://doi.org/10.1084/jem.20240010), identify defective RNA processing as the root cause of impaired antiviral immunity against SARS-CoV2 in the human brainstem. These studies provide molecular insight into virus-associated severe brainstem encephalitis through PKR inactivation.

5 June 2026 in The EMBO Journal
Verified
Journal Article
Open access
LKLuisa Krumwiede
Luisa Krumwiede
DHDavid Hollaus
David Hollaus
EVErika Valeri
Erika Valeri
KSKarina Schindler-Schumitsch
Karina Schindler-Schumitsch
MBMonika A Bazyl
Monika A Bazyl
MGMoritz M Gaidt
Moritz M Gaidt
The antiviral protein MORC3 is frequently inhibited by viruses. To counteract viral antagonism, MORC3 represses a noncanonical pathway of type-I-interferon (IFN) such that viral inhibition of MORC3 triggers ( > 10,000-fold) IFN induction. How MORC3 represses this pathway, and why IFN induction upon MORC3 loss is so potent without canonical IRF3/7 transcription factors, is unknown. Here, we show that MORC3 restricts chromatin accessibility at tandem repeat elements harboring up to 61 homotypic transcription factor motifs. One such element becomes a potent enhancer of IFNB1 upon MORC3 loss. Its motif cluster contains 45 PU.1 binding sites and is necessary and sufficient for MORC3-mediated repression and enhancer activity upon MORC3 loss. PU.1 recruits MORC3 to repress this enhancer by recruiting DAXX and enabling H3.3 incorporation. Upon MORC3 loss, PU.1 drives IRF3/7-independent IFN induction. Other restricted tandem repeats contain homotypic motif clusters of SPI, AP-1, and SP/KLF transcription factors. Our findings uncover a TF motif cluster–driven repression mechanism by MORC3 at tandem repeats, enabling specific repression of an IFNB1 enhancer such that viral antagonism of MORC3 induces interferon.